English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduFor the first time, a medication has impacted heart muscle thickness and function for patients with the most common inherited heart condition, hypertrophic cardiomyopathy, rather than simply addressing their symptoms.
Tag: AHA Scientific Sessions
A Novel Monoclonal Antibody Therapy Cuts LDL Cholesterol by Half in a High-Risk Patient Population, Study Shows
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.